Kaplan-Meier survival analysis suggested a trend towardsimproved survival in the DPP-4 inhibitor group (HR=0.834, 95% CI:0.6–1.04, p=0.05), particularly among patients with chronic kidneydisease (CKD), although without statistical significance. This evidence concerns the gene DPP4 and chronic kidney disease.